Moshe Gatt

28PUBLICATIONS
83CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Gene and molecular therapyAutoimmunityHaematology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (28)

|May 12, 2026
Daratumumab-Bortezomib-Cyclophosphamide-Dexamethasone in Newly Diagnosed Amyloidosis: ANDROMEDA Final Survival Analysis.

|Apr 14, 2026
Viral Reactivation in Multiple Myeloma Patients Receiving Anti-BCMA Chimeric Antigen Receptor T-Cell Therapy.

Ido Cohen, Eyal Lebel, Sigal Grisariu

|Dec 10, 2025
Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study.

Rakesh Popat, Meral Beksac, Meletios A Dimopoulos

|Nov 13, 2025
High Rate of Cytokine Release Syndrome-Related Coagulopathy with Low Incidence of Bleeding and Thrombosis in Patients Treated with B-Cell Maturation Antigen (BCMA)-Targeted Chimeric Antigen Receptor T-Cells (CAR-T).

Ariela Arad, Maya Katz, Eyal Lebel

|Apr 25, 2025
A phase 2 randomized study of modakafusp alfa as a single agent for patients with relapsed/refractory multiple myeloma.

Sarah A Holstein, Shebli Atrash, Hira Mian

|Dec 09, 2024
Efficacy and Safety of Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell for the Treatment of Relapsed and Refractory AL Amyloidosis.

Eyal Lebel, Nathalie Asherie, Shlomit Kfir-Erenfeld

Pageof 5

Frequent Collaborators

7 joint publications

Eyal Lebel

6 joint publications

Nathalie Asherie

6 joint publications

Adir Shaulov

5 joint publications

Batia Avni